{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,31]],"date-time":"2026-10-31T01:39:28Z","timestamp":1793410768519,"version":"4.5.0"},"reference-count":13,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,3,10]],"date-time":"2026-03-10T00:00:00Z","timestamp":1773100800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,4,16]],"date-time":"2026-04-16T00:00:00Z","timestamp":1776297600000},"content-version":"vor","delay-in-days":37,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Gastroenterol"],"DOI":"10.1186\/s12876-026-04723-7","type":"journal-article","created":{"date-parts":[[2026,3,10]],"date-time":"2026-03-10T02:44:49Z","timestamp":1773110689000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["High-intensity hydrophilic versus lipophilic statins in patients with primary biliary cholangitis: a multi-institutional analysis"],"prefix":"10.1186","volume":"26","author":[{"given":"Hussam","family":"Kawas","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohammad","family":"Alabbas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohamad-Noor","family":"Abu-Hammour","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Barish","family":"Eren","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Walid","family":"Hazem","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Omar T.","family":"Sims","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dian-Jung","family":"Chiang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,3,10]]},"reference":[{"key":"4723_CR1","doi-asserted-by":"publisher","first-page":"1053","DOI":"10.1016\/S0140-6736(24)01303-5","volume":"404","author":"A Tanaka","year":"2024","unstructured":"Tanaka A, Ma X, Takahashi A, et al. Primary biliary cholangitis. Lancet. 2024;404:1053\u201366. https:\/\/doi.org\/10.1016\/S0140-6736(24)01303-5.","journal-title":"Lancet"},{"issue":"6","key":"4723_CR2","doi-asserted-by":"publisher","first-page":"879","DOI":"10.1016\/j.aohep.2019.07.006","volume":"18","author":"L Castillo","year":"2019","unstructured":"Castillo L, Gayt\u00e1n-Santill\u00e1n A, L\u00f3pez-Tello A, et al. Patterns of serum lipid derangements and cardiovascular risk assessment in patients with primary biliary cholangitis. Ann Hepatol. 2019;18(6):879\u201384. https:\/\/doi.org\/10.1016\/j.aohep.2019.07.006.","journal-title":"Ann Hepatol"},{"issue":"2","key":"4723_CR3","doi-asserted-by":"publisher","first-page":"265","DOI":"10.1136\/gut.51.2.265","volume":"51","author":"M Longo","year":"2002","unstructured":"Longo M, Crosignani A, Battezzati P, et al. Hyperlipidaemic state and cardiovascular risk in primary biliary cirrhosis. Gut. 2002;51(2):265\u20139. https:\/\/doi.org\/10.1136\/gut.51.2.265.","journal-title":"Gut"},{"issue":"Suppl1","key":"4723_CR4","doi-asserted-by":"publisher","first-page":"A16394","DOI":"10.1161\/circ.148.suppl_1.16394","volume":"148","author":"M Iskander","year":"2023","unstructured":"Iskander M, Patel A, Mintz J, et al. Abstract 16394: Increasing prevalence of cardiovascular comorbidities among patients with primary biliary cirrhosis: 2012\u20132020. Circulation. 2023;148(Suppl1):A16394. https:\/\/doi.org\/10.1161\/circ.148.suppl_1.16394.","journal-title":"Circulation"},{"issue":"7","key":"4723_CR5","doi-asserted-by":"publisher","first-page":"2086","DOI":"10.1007\/s10620-009-0988-9","volume":"55","author":"M Rajab","year":"2010","unstructured":"Rajab M, Kaplan MM. Statins in primary biliary cirrhosis: are they safe? Dig Dis Sci. 2010;55(7):2086\u20138. https:\/\/doi.org\/10.1007\/s10620-009-0988-9.","journal-title":"Dig Dis Sci"},{"key":"4723_CR6","doi-asserted-by":"publisher","first-page":"687585","DOI":"10.3389\/fcvm.2021.687585","volume":"8","author":"E Climent","year":"2021","unstructured":"Climent E, Benaiges D, Pedro-Botet J. Hydrophilic or lipophilic statins? Front Cardiovasc Med. 2021;8:687585. https:\/\/doi.org\/10.3389\/fcvm.2021.687585.","journal-title":"Front Cardiovasc Med"},{"issue":"6","key":"4723_CR7","doi-asserted-by":"publisher","first-page":"1946","DOI":"10.1002\/hep.21741","volume":"46","author":"T Stojakovi\u0107","year":"2007","unstructured":"Stojakovi\u0107 T, Putz-Bankuti C, Fauler G, et al. Atorvastatin in patients with primary biliary cirrhosis and incomplete biochemical response to ursodeoxycholic acid. Hepatology. 2007;46(6):1946\u201352. https:\/\/doi.org\/10.1002\/hep.21741.","journal-title":"Hepatology"},{"issue":"8","key":"4723_CR8","doi-asserted-by":"publisher","first-page":"809","DOI":"10.1080\/17425255.2020.1801634","volume":"16","author":"T Hirota","year":"2020","unstructured":"Hirota T, Fujita Y, Ieiri I. An updated review of pharmacokinetic drug interactions and pharmacogenetics of statins. Expert Opin Drug Metab Toxicol. 2020;16(8):809\u201322. https:\/\/doi.org\/10.1080\/17425255.2020.1801634.","journal-title":"Expert Opin Drug Metab Toxicol"},{"issue":"23","key":"4723_CR9","doi-asserted-by":"publisher","first-page":"2171","DOI":"10.1056\/NEJMoa1714519","volume":"378","author":"C Corpechot","year":"2018","unstructured":"Corpechot C, Chazouill\u00e8res O, Rousseau A, et al. A placebo-controlled trial of bezafibrate in primary biliary cholangitis. N Engl J Med. 2018;378(23):2171\u201381. https:\/\/doi.org\/10.1056\/NEJMoa1714519.","journal-title":"N Engl J Med"},{"issue":"5","key":"4723_CR10","doi-asserted-by":"publisher","first-page":"858","DOI":"10.1002\/hep.1840150518","volume":"15","author":"JS Crippin","year":"1992","unstructured":"Crippin JS, Lindor KD, Jorgensen R, et al. Hypercholesterolemia and atherosclerosis in primary biliary cirrhosis: what is the risk? Hepatology. 1992;15(5):858\u201362. https:\/\/doi.org\/10.1002\/hep.1840150518.","journal-title":"Hepatology"},{"issue":"6","key":"4723_CR11","doi-asserted-by":"publisher","first-page":"e0179","DOI":"10.1097\/HC9.0000000000000179","volume":"7","author":"J Trivella","year":"2023","unstructured":"Trivella J, John BV, Levy C. Primary biliary cholangitis: epidemiology, prognosis, and treatment. Hepatol Commun. 2023;7(6):e0179. https:\/\/doi.org\/10.1097\/HC9.0000000000000179.","journal-title":"Hepatol Commun"},{"issue":"8","key":"4723_CR12","doi-asserted-by":"publisher","first-page":"1334","DOI":"10.1136\/gutjnl-2024-333074","volume":"73","author":"A Arparpour","year":"2024","unstructured":"Arparpour A, Teh K, Mahgoub S, et al. Long-term liver-related outcomes and liver stiffness progression of statin usage in steatotic liver disease. Gut. 2024;73(8):1334\u201342. https:\/\/doi.org\/10.1136\/gutjnl-2024-333074.","journal-title":"Gut"},{"issue":"2","key":"4723_CR13","doi-asserted-by":"publisher","first-page":"374","DOI":"10.1016\/j.jhep.2011.07.023","volume":"56","author":"X Zhou","year":"2012","unstructured":"Zhou X, Kim S, Yip T, et al. Hepatotoxicity associated with statins: reports of idiosyncratic liver injury post-marketing. J Hepatol. 2012;56(2):374\u201380. https:\/\/doi.org\/10.1016\/j.jhep.2011.07.023.","journal-title":"J Hepatol"}],"container-title":["BMC Gastroenterology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12876-026-04723-7","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12876-026-04723-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12876-026-04723-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,16]],"date-time":"2026-04-16T09:57:15Z","timestamp":1776333435000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s12876-026-04723-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3,10]]},"references-count":13,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["4723"],"URL":"https:\/\/doi.org\/10.1186\/s12876-026-04723-7","relation":{},"ISSN":["1471-230X"],"issn-type":[{"value":"1471-230X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,3,10]]},"assertion":[{"value":"10 December 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 March 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 March 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This retrospective study utilized de-identified patient data from TriNetX and was exempt from institutional review board approval.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not Applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"236"}}